Advances in Therapy

, Volume 27, Issue 5, pp 285–296 | Cite as

Castration-refractory prostate cancer: New drugs in the pipeline

Review

Abstract

The standard treatment for patients with castration-refractory prostate cancer (CRPC) is the combination docetaxel-prednisone, if the patient can support chemotherapy. Several new treatments have been tested in chemotherapy-naïve or docetaxel-pretreated patients with CRPC. Some of these treatments have shown activity in first-line and second-line treatment. In this review, an update is given of new treatment studies performed in patients with CRPC.

Keywords

castration-refractory prostate cancer docetaxel cabazitaxel abiraterone acetate angiogenesis modulators vaccines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mathers C, Boschi-Pinto C, Lopez A. Murray C. Cancer incidence, mortality and survival by site for 14 regions of the world. Available at: www.who.int/healthinfo/paper13.pdf. Accessed May 21, 2010.Google Scholar
  2. 2.
    Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004;351:1488–1490.CrossRefPubMedGoogle Scholar
  3. 3.
    Schrijvers D. Androgen-independent prostate cancer. Recent Results Cancer Res. 2007;175:239–249.CrossRefPubMedGoogle Scholar
  4. 4.
    Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–1764.PubMedGoogle Scholar
  5. 5.
    Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF; TAX 327 Investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol. 2008;19:1749–1753.CrossRefPubMedGoogle Scholar
  6. 6.
    Loriot Y, Massard C, Gross-Goupil M, et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol. 2009;20:703–708.CrossRefPubMedGoogle Scholar
  7. 7.
    Sternberg CN, Petrylak DP, Sartor O et al. Multinational, double-blind, phase iii study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27:5431–5438.CrossRefPubMedGoogle Scholar
  8. 8.
    Eisenhauer EA, Therasse P, Bogaerts PJ, et al. New response evaluation in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.CrossRefPubMedGoogle Scholar
  9. 9.
    Hahn NM, Zon RT, Yu M et al. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Ann Oncol. 2009;20:1971–1976.CrossRefPubMedGoogle Scholar
  10. 10.
    Kelly WK. Epothilones in prostate cancer. Urol Oncol. 2010. Nov 12 [Epub ahead of print].Google Scholar
  11. 11.
    Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol. 2009; 20:492–497.CrossRefPubMedGoogle Scholar
  12. 12.
    Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007;110:556–563.CrossRefPubMedGoogle Scholar
  13. 13.
    Rosenberg JE, Ryan CJ, Weinberg VK, et al. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol. 2009;27:2772–2778.CrossRefPubMedGoogle Scholar
  14. 14.
    Galmarini CM. Sagopilone, a microtubule stabilizer for the potential treatment of cancer. Curr Opin Investig Drugs. 2009;10:1359–1371.PubMedGoogle Scholar
  15. 15.
    Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs. 2010;21:433–438.CrossRefPubMedGoogle Scholar
  16. 16.
    Drug Discovery & Development Magazine. Phase 3 cabazitaxel trial shows improved survival. Available at: www.dddmag.com/news-Phase-3-Cabazitaxel-Trial-Shows-Improved-Survival-3410.aspx. Accessed May 21, 2010.Google Scholar
  17. 17.
    Yap TA, Carden CP, Attard G, de Bono JS. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol. 2008;8:449–457.CrossRefPubMedGoogle Scholar
  18. 18.
    Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–4571.CrossRefPubMedGoogle Scholar
  19. 19.
    Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel. J Clin Oncol. 2010;28:1496–1501.CrossRefPubMedGoogle Scholar
  20. 20.
    Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010;28:1489–1495.CrossRefPubMedGoogle Scholar
  21. 21.
    Attard G, Reid AH, A’Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742–3748.CrossRefPubMedGoogle Scholar
  22. 22.
    Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28:1481–1488.CrossRefPubMedGoogle Scholar
  23. 23.
    Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 2009;10:981–991.CrossRefPubMedGoogle Scholar
  24. 24.
    Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–790.CrossRefPubMedGoogle Scholar
  25. 25.
    Aragon-Ching JB, Madan RA, Dahut WL. Angiogenesis inhibition in prostate cancer: current uses and future promises. J Oncol. 2010;Feb 11 [Epub ahead of print].Google Scholar
  26. 26.
    Aragon-Ching JB, Dahut WL. VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol. 2009;2:161–168.CrossRefPubMedGoogle Scholar
  27. 27.
    Ning YM, Gulley JL, Arlen PM, et al. Phase II Trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:2070–2076.CrossRefPubMedGoogle Scholar
  28. 28.
    Chi KN, Ellard SL, Hotte SJ, et al. A phase II study of sorafenib in patients with chemo-naive castrationresistant prostate cancer. Ann Oncol. 2008;19:746–751.CrossRefPubMedGoogle Scholar
  29. 29.
    Aragon-Ching JB, Jain L, Gulley JL, et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int. 2009;103:1636–1640.CrossRefPubMedGoogle Scholar
  30. 30.
    Safarinejad MR. Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study. Urol Oncol. 2010;28:21–27.PubMedGoogle Scholar
  31. 31.
    Steinbild S, Mross K, Frost A, et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer. 2007;97:1480–1485.CrossRefPubMedGoogle Scholar
  32. 32.
    Mena AC, Pulido EG, Guillén-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs. 2010;21(suppl. 1):S3–S11.CrossRefPubMedGoogle Scholar
  33. 33.
    Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castrationresistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol. 2010;21:319–324.CrossRefPubMedGoogle Scholar
  34. 34.
    Dror Michaelson M, Regan MM, Oh WK, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol. 2009;20:913–920.CrossRefGoogle Scholar
  35. 35.
    De Sanctis JB, Mijares M, Suárez A, et al. Pharmacological properties of thalidomide and its analogues. Recent Pat Inflamm Allergy Drug Discov. 2010;4:144–148.CrossRefPubMedGoogle Scholar
  36. 36.
    Drake MJ, Robson W, Mehta P, Schofield I, Neal DE, Leung HY. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003;88:822–827.CrossRefPubMedGoogle Scholar
  37. 37.
    Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001;7:1888–1893.PubMedGoogle Scholar
  38. 38.
    Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2532–2539.CrossRefPubMedGoogle Scholar
  39. 39.
    Bagnato A, Spinella F, Rosanò L. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol. 2008;86:473–484.CrossRefPubMedGoogle Scholar
  40. 40.
    Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008;113:2478–2487.CrossRefPubMedGoogle Scholar
  41. 41.
    Armstrong AJ, Creel P, Turnbull J, et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2008;14:6270–6276.CrossRefPubMedGoogle Scholar
  42. 42.
    Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int. 2009;103:434–440.CrossRefPubMedGoogle Scholar
  43. 43.
    Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res. 2009;15:3540–3549.CrossRefPubMedGoogle Scholar
  44. 44.
    Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2009;15:7421–7428.CrossRefPubMedGoogle Scholar
  45. 45.
    Lara PN Jr, Longmate J, Evans CP, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009;20:179–184.CrossRefPubMedGoogle Scholar
  46. 46.
    Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy. Br J Cancer. 2009;100:1523–1529.CrossRefPubMedGoogle Scholar
  47. 47.
    Rizzi F, Bettuzzi S. Clusterin (CLU) and prostate cancer. Adv Cancer Res. 2009;105:1–19.CrossRefPubMedGoogle Scholar
  48. 48.
    Chi KN, Zoubeidi A, Gleave ME. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drugs. 2008;17:1955–1962.CrossRefPubMedGoogle Scholar
  49. 49.
    Sowery RD, Hadaschik BA, So AI, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int. 2008;102:389–397.CrossRefPubMedGoogle Scholar
  50. 50.
    Chi KN, Hotte SJ, Yu E, et al. Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC). Eur J Cancer. 2009;2(suppl. 7):406.Google Scholar
  51. 51.
    Abbas A, Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics. 2008;3:300–309.CrossRefPubMedGoogle Scholar
  52. 52.
    Molife LR, Attard G, Fong PC, et al. Phase II, twostage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol. 2010;21:109–113.CrossRefPubMedGoogle Scholar
  53. 53.
    Cha E, Fong L. Therapeutic vaccines for prostate cancer. Curr Opin Mol Ther. 2010;12:77–85.PubMedGoogle Scholar
  54. 54.
    Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18:1001–1011.CrossRefPubMedGoogle Scholar
  55. 55.
    Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099–1105.CrossRefPubMedGoogle Scholar
  56. 56.
    Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670–3679.CrossRefPubMedGoogle Scholar
  57. 57.
    Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSFsecreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008;113:975–984.CrossRefPubMedGoogle Scholar
  58. 58.
    Slovin SF, Kelly WK, Wilton A, et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2009;7:E77–E82.CrossRefPubMedGoogle Scholar
  59. 59.
    Ziada A, Barqawi A, Glode LM, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate. 2004;60:332–327.CrossRefPubMedGoogle Scholar
  60. 60.
    De Bono JS, Fizazi K, Flechon A, et al. Randomized phase II study of CNTO 328 (C), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone (M) versus M alone in metastatic castration-resistant prostate cancer (CRPC). Presented at: ASCO 2010 Genitourinary Cancers Symposium. Available at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30763. Accessed May 21, 2010.Google Scholar

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  • Dirk Schrijvers
    • 1
  • Peter Van Erps
    • 2
  • Jim Cortvriend
    • 2
  1. 1.Department of Hemato-OncologyZiekenhuisnetwerk Antwerpen-MiddelheimAntwerpBelgium
  2. 2.Department of UrologyZiekenhuisnetwerk Antwerpen-MiddelheimAntwerpBelgium

Personalised recommendations